Pneumonia, Pneumococcal Therapeutic Market ANALISI DIMENSIONE E QUOTA - TENDENZE DI CRESCITA E PREVISIONI (2024 - 2031)
Pneumonia, Pneumococcal Therapeutic Market is segmented By Route of Administration (Oral, Intravenous, Subcutaneous, Parenteral, Topical), By Molecule Type (Recombinant Fusion Proteins, Small Molecule, Monoclonal Antibody, Peptide Polymer, Gene Therapy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Pneumonia, Pneumococcal Therapeutic Market Size
Dimensione del Mercato in USD Bn
CAGR8.4%
| Periodo di Studio | 2024 - 2031 |
| Anno di Base per la Stima | 2023 |
| CAGR | 8.4% |
| Concentrazione del Mercato | Medium |
| Principali Attori | Biotest AG, Vaxcyte, Inc., Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc. and Among Others. |
please let us know !
Pneumonia, Pneumococcal Therapeutic Market Analysis
The pneumonia, pneumococcal therapeutic market is estimated to be valued at USD 2.72 Billion in 2024 and is expected to reach USD 4.77 Billion by 2031, growing at a compound annual growth rate (CAGR) of 8.4% from 2024 to 2031. The growing geriatric population and increased risk of pneumonia among the elderly is driving the demand. Furthermore, rising pollution levels and environmental factors leading to higher prevalence of respiratory illnesses are also boosting the market growth.